Samsung Biologics Begins Construction on Fourth Biopharma Manufacturing Plant

Published on: 

The new super plant, being built in Incheon, South Korea, will have a total biopharmaceutical manufacturing capacity of 256,000 L.

Samsung Biologics has officially begun construction on a fourth plant (Plant 4) in Incheon, South Korea. The multi-story, 238,000-m2 biopharmaceutical manufacturing plant will have a total manufacturing capacity of 256,000 L, the company announced in a Nov. 18, 2020 press release.

Upon completion of Plant 4, Samsung Biologics expects to be accountable for a third of the total global biopharmaceutical contract manufacturing organization (CMO) manufacturing capacity with a combined sum of 620,000 L of capacity from a single site. Plant 4 will have a modular design that will allow flexibility for certain parts of the plant to begin manufacturing activities by the end of 2022. Full operations are expected to be on line in 2023.

Equipment and instruments will be fully implemented with data integrity and cybersecurity to reduce risk and to allow real-time secure access to information. The new facility will also be capable of designing to scale the varying needs of clients, from large-scale commercial manufacturing to small-scale CMO. Plant 4’s manufacturing flexibility will be based on a diverse line-up of bioreactors ranging from 2000 L to 10,000 L to 15,000 L. Plant 4 will also provide a full range of contract development organization, CMO, and contract research organization processes as well as early stage development capabilities and large-scale commercial manufacturing with a full quality control lab.


Source: Samsung Biologics